Century Therapeutics (IPSC) Proxy filing summary

Executive summary

• Annual Meeting scheduled for June 11, 2026, at 9:00 a.m. Eastern Time, to be held virtually.

• Proxy materials, including the Notice, Proxy Statement, and Annual Report, are available online for review and voting.

Voting matters and shareholder proposals

• Election of two Class II directors, Alessandro Riva, M.D., and Han Lee, Ph.D., M.B.A., for a three-year term expiring in 2029.

• Ratification of Ernst & Young LLP as the independent registered public accounting firm for 2026.

• Proposal to amend the Certificate of Incorporation to increase authorized common stock from 300,000,000 to 450,000,000.

• Proposal to approve adjournment of the meeting if there are insufficient votes to approve the Charter Amendment Proposal.

• Board recommends voting FOR all nominees and all proposals.

Board of directors and corporate governance

• Board nominates Alessandro Riva, M.D., and Han Lee, Ph.D., M.B.A., for re-election as Class II directors.